Article Details

Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM)

Retrieved on: 2025-03-09 13:43:21

Tags for this article:

Click the tags to see associated articles and topics

Morgan Stanley Reaffirms Overweight Rating for Cullinan Therapeutics (NASDAQ:CGEM). View article details on hiswai:

Excerpt

They presently have a $35.00 price objective on the stock, down from their prior price objective of $38.00. Morgan Stanley's price objective would ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up